Abstract:
The present invention provides canine heavy chain and light chain (both .lambda. and .kappa.) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised of the presen t disclosed canine variable domain framework sequences and CDRs specific for a n antigen obtained from antibodies from other than canines (preferably mouse). The invention also provides methods of making caninized antibodies and using them. This disclosure specifically describes caninized antibodies that are useful in the treatment of canine allergy. The general process of caninizati on permits the development of useful therapeutics, which includes but is not limited to allergy, osteoarcomma's and lymphomma's.
Abstract:
The present invention provides canine heavy chain and light chain (both .lambda. and .kappa.) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised of the presen t disclosed canine variable domain framework sequences and CDRs specific for a n antigen obtained from antibodies from other than canines (preferably mouse). The invention also provides methods of making caninized antibodies and using them. This disclosure specifically describes caninized antibodies that are useful in the treatment of canine allergy. The general process of caninizati on permits the development of useful therapeutics, which includes but is not limited to allergy, osteoarcomma's and lymphomma's.